Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live
Company

Astellas Pharma

Tracked across 3 events · 53 articles · First seen Apr 20, 2026 · Last active Jun 30, 2026

Sentiment
-17
Attention
6
Events
3
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 10
Regulatory
Impact: Astellas Pharma is one of the few mid-sized drug companies that confirmed its application to the United States — Medicaid pilot program, viewing it as a constructive path forward in a complex policy environment.
Apr 20, 2026 · 6 articles
4 -20
Regulatory
Impact: Astellas Pharma is the manufacturer of the reference listed drug Xtandi Tablets, to which Lupin (company)'s Enzalutamide Tablets were found bioequivalent. This approval could introduce competition for Astellas Pharma's product.
Jun 26, 2026 · 16 articles
4 -40
Business
Impact: Astellas Pharma's stock declined, showing a negative performance.
May 21, 2026 · 31 articles
ERGEN INTELLIGENCE
Track Astellas Pharma live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.